GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

Researchers are engineering a new class of miniature antibodies, called intrabodies, that can operate inside living cells to ...

New treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and motor neuron disease (MND) could be unlocked thanks to microscopic medicines developed by researchers at the University ...

New findings suggest that targeting inflammation in Alzheimer’s may matter as much as targeting protein buildup.

Rural Americans face higher Alzheimer's risk but often lack access to specialists and early diagnostic tools, prompting calls ...

Anavex’s precision medicine approach recognizes that Alzheimer’s pathology is heterogeneous, but autophagy dysfunction represents a causative co-factor that precedes divergent downstream ...

What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next ...

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular ...

Alzheimer’s disease is a progressive neurodegenerative disease that affects an individual’s behavior, memory, and mental capabilities. Alzheimer’s allows for the build-up of proteins in the brain, ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease.

Viagra, a popular erectile dysfunction medication, may be the world's only existing treatment against Alzheimer's disease, according to over 20 experts. Previous research also shows that the compound ...

People with Alzheimer's disease often have other neurodegenerative conditions as well, including a less-understood disorder ...